Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Taiwan · Delayed Price · Currency is TWD

78.60

-0.80 (-1.01%)

Aug 28, 2026, 1:30 PM CST

Lumosa Therapeutics Financials Overview

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	34.37	35.83	39.15	56.92	26.64	17.36
Revenue Growth	-7.74%	-8.49%	-31.21%	113.63%	53.45%	-19.81%
Gross Profit	18.28	21.87	17.71	41.48	14.56	9.89
Operating Income	-303.41	-333.49	-357.12	-375.78	-305.92	-430.28
Net Income	-370.06	-340.54	-424.78	-238.04	-494.66	95.95
Earnings Per Share	-2.23	-2.05	-2.60	-1.47	-3.05	0.64
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Asia	8.9	13.46	11.65	25.61	2	2.33
Taiwan	25.47	22.37	27.33	15.41	21.24	15.04
America	-	-	0.18	7.56	3.19	-
Total	34.37	35.83	39.15	56.92	26.64	17.36

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	633	798.34	1,353	844.31	1,185	1,452
Total Debt	3.48	6.92	8.48	12.61	4.69	11.49
Net Cash (Debt)	629.52	791.42	1,344	831.7	1,180	1,441
Net Cash Growth	-38.01%	-41.13%	61.64%	-29.51%	-18.10%	14.89%
Net Cash Per Share	3.79	4.76	8.22	5.12	7.26	9.55

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-261.39	-360.5	-296.33	-328.21	-300.46	-452.6
Capital Expenditures	-	-0.67	-0.45	-14.32	-2.29	-0.09
Free Cash Flow	-261.39	-361.16	-296.78	-342.53	-302.74	-452.69
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	53.18%	61.05%	45.24%	72.88%	54.65%	56.96%
Operating Margin	-882.84%	-930.73%	-912.09%	-660.23%	-1148.26%	-2478.27%
Pretax Margin	-1091.93%	-967.37%	-1115.69%	-439.39%	-1893.42%	552.62%
Profit Margin	-1076.78%	-950.41%	-1084.91%	-418.23%	-1856.70%	552.62%
FCF Margin	-760.58%	-1007.96%	-757.97%	-601.82%	-1136.33%	-2607.34%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 29, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	-	-	-	-	63.75
PS Ratio	383.05	914.46	1078.41	197.97	241.17	352.32